BioSpace1h
Merck’s Winrevair Cuts Morbidity, Mortality Risk by Over 75% in Phase III PAH Study
In high-risk patients with pulmonary arterial hypertension, Merck ’s fusion protein therapeutic Winrevair reduced the ...
Fierce Pharma1d
Merck's Winrevair slashes mortality-morbidity risk by 76%
The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so ...
MPR21h
Sotatercept Reduces Major Events in High-Risk PAH Patients
Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) functional class (FC) 3 or 4 at ...
Managed Healthcare Executive1d
Winrevair Reduced Risk of Morbidity and Mortality by 76% in PAH | ACC 2025
In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension ...
The American Journal of Managed Care1d
Sotatercept Reduces Risk of Death, Transplant, or Hospitalization in Advanced PAH
Patients taking sotatercept had a 76% relative risk reduction in morbidity and mortality events compared with patients taking ...